A breakdown of all the ligands targeting the LAG3 receptor on CD8+ T cells, regardless of cancer cell EMT status or tumor immune phenotype, showed that most ligands for LAG3 are HLA II molecules, with LGALS3 being the only non-MHC related ligand (Fig. 5b). Here, LAG3 is linked to neoplasm.